CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. AGIOa leader in breakthrough therapies for cellular metabolism in rare diseases, today announced that
– Actively initiating the Phase 3 ENERGIZE and ENERGIZE-T studies evaluating PYRUKYND® in adults with non-transfusion-dependent or transfusion-dependent α- or β-thalassemia – – Agios to
CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. AGIO, a leader in breakthrough cellular therapies for rare and genetically defined diseases, today
As remote work becomes a permanent fixture of American employment, a new national study from John Foy & Associates uncovers the rising dangers hiding behind
A groundbreaking new analysis from High Rise Financial highlights a severe and escalating crisis inside U.S. nursing homes, where tens of thousands of elderly residents
Under Florida’s no-fault system, your PIP pays medical bills (typically 80%) and lost wages (about 60%) after a crash, regardless of fault, but prompt action is crucial. Get treatment within